GEMINI EXPLORATIONS INC UPDATES LOS CHORROS PHASE TWO WORK PROGRAM

Stocks to Watch: Gemini Explorations, Inc.  (OTCBB: GXPI), H&E Equipment Services, Inc. (NasdaqGS:HEES) , Lev Pharmaceuticals, Inc. (OTCBB:LEVP) , Spectrum Brands, Inc. (NYSE:SPC) , Nabi Biopharmaceuticals  (Nasdaq:NABI)

Featured Stock: Gemini Explorations, Inc.

(OTCBB: GXPI)

Current Price (0.16)

http://www.wallstreetstockreview.com/

GEMINI EXPLORATIONS INC UPDATES LOS CHORROS PHASE TWO WORK PROGRAM

Calgary, AB - November 12, 2007-- Gemini Explorations Inc, (“Gemini”) OTCBB:GXPI, is pleased to report that Minera Primecap Geological Services (MPGS) has commenced work on a detailed topographical survey of the Los Chorros Gold Project. The survey will be detailed on a 1:1000 scale with contours spaced every 5 meters. Minera Primecap Geological Services (MPGS) will perform the survey and detailed map preparation. MPGS has also reported that the drill program along the main vein be set at 50 meter spacings with depths ranging between 160 and 340 meters. Carlos Alberto Vera, Chief geologist of MPGS believes that if the predicted drill program throws positive results the resource estimate would be increased by 30% in the exposed areas of the mine.

The Los Chorros Mine is currently being mined with extremely antiquated equipment and Gemini believes that the project could be turned into a highly efficient producing gold project with low capital costs. Current mining operations at Los Chorros recover a low percentage of the available gold and precious metals present on the property. The plant would initially run at 30 to 50 tonnes/day with a targeted production rate of 100 tonnes per day during the first year. Gemini reported on November 5, 2007 that a 100 tonne per day production rate would produce US$1,080,280 monthly and over US$12,900,000 annually. These estimates are based on US$730 per ounce gold with US$200 per ounce operating and production costs netting US$530 per ounce.

Notice Regarding Forward Looking Statements

This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.  Such forward-looking statements include, among other things, the expectation of the gold production of the property to be acquired, the low capital costs to upgrade the Los Chorros operating plant, the assumed production and net cash flow.Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration.  These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.  Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.  Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the 2006 fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Michael Hill

President

Gemini Explorations, Inc

Suite 103, 240-11^th Ave SW

Calgary, AB T2R 0C3

http://www.geminiexploration.com/  email: info@geminiexploration.com

IR info: 1 877 700 1644

For an in-depth analyst report, please visit: http://www.wallstreetstockreview.com/

H&E Equipment Services, Inc.

(NasdaqGS:HEES)

Current Price (18.34)

www.WallstreetStockReview.com

BATON ROUGE, La.--Nov. 8--H&E Equipment Services, Inc. (NASDAQ:HEES - News) (the “Company”) announced today that its Board of Directors has authorized a stock repurchase program, under which the Company may purchase, from time to time, in open market transactions at prevailing prices or through privately negotiated transactions as conditions permit, up to $100 million of the Company’s outstanding common stock. The repurchase program is expected to continue until December 31, 2008 unless extended or shortened by the Board of Directors. The Company expects to fund the repurchases of the Company’s common stock with working capital and/or borrowings under the Company’s existing credit facility.                   The Company is one of the largest integrated equipment services companies in the United States with 62 full-service facilities throughout the West Coast, Intermountain, Southwest, Gulf Coast, Southeast and Mid-Atlantic regions of the United States. The Company is focused on heavy construction and industrial equipment and rents, sells and provides parts and service support for four core categories of specialized equipment: (1) hi-lift or aerial platform equipment; (2) cranes; (3) earthmoving equipment; and (4) industrial lift trucks. By providing equipment rental, sales, and on-site parts, repair and maintenance functions under one roof, the Company is a one-stop provider for its customers’ varied equipment needs. This full service approach provides the Company with multiple points of customer contact, enabling it to maintain a high quality rental fleet, as well as an effective distribution channel for fleet disposal and provides cross-selling opportunities among its new and used equipment sales, rental, parts sales and service operations.

Lev Pharmaceuticals, Inc.

(OTCBB:LEVP)

Current Price (1.80)

www.WallstreetStockReview.com

NEW YORK, Nov. 9 -- Lev Pharmaceuticals, Inc. (OTC Bulletin Board: LEVP.OB - News) today announced that it will conduct a conference call and audio web cast on Tuesday, November 13, 2007, at 1:00 p.m. Eastern Time (ET), in conjunction with the release of its financial results for the third quarter ended September 30, 2007. Lev anticipates releasing its financial results at 7:00 a.m. ET on Tuesday, November 13, 2007.              Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's C1 inhibitor, proposed to be marketed as Cinryze(TM), has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. Lev has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs. Lev is also evaluating the development of C1 inhibitor for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

Spectrum Brands, Inc.

(NYSE:SPC)

Current Price (4.99)

www.WallstreetStockReview.com

ATLANTA--Nov. 8--Spectrum Brands, Inc. (NYSE:SPC - News) announced fourth quarter net sales of $548.2 million and a net loss of $6.60 per share for the quarter ended September 30, 2007. Excluding certain items which management believes are not indicative of the company’s on-going normalized operations, the company generated diluted earnings per share of $0.23.                  Spectrum Brands is a global consumer products company and a leading supplier of batteries, portable lighting, lawn and garden products, household insect control, shaving and grooming products, personal care products and specialty pet supplies. Spectrum Brands’ products are sold by the world’s top 25 retailers and are available in more than one million stores in 120 countries around the world. Headquartered in Atlanta, Georgia, Spectrum Brands generated fiscal year 2007 net sales of $2.0 billion and has approximately 7,500 employees worldwide. The company’s stock trades on the New York Stock Exchange under the symbol SPC.

Nabi Biopharmaceuticals

(Nasdaq:NABI)

Current Price (3.44)

www.WallstreetStockReview.com

BOCA RATON, Fla., Nov. 8-- Nabi Biopharmaceuticals (Nasdaq: NABI - News) today announced its third quarter financial results. The company recorded a net loss of $15.9 million, or $0.26 per share, for the quarter ended September 29, 2007, which included $7.5 million, or $0.12 per share, of expenses for unusual items described below. This was an improvement of 27% when compared to the net loss of $21.8 million, or $0.36 per share, for the quarter ended September 30, 2006, which included a loss of $5.5 million, or $0.09 per share, from discontinued operations. Revenues for the third quarter of 2007 were $20.1 million compared to $19.6 million in 2006. Nabi- HB® [Hepatitis B Immune Globulin (Human)] revenues were $7.4 million during the third quarter of 2007 compared to $6.8 million during the third quarter of 2006.                                   Nabi Biopharmaceuticals develops and markets products that target serious medical conditions in the areas of transplantation, infectious disease, nicotine addiction, and hematology/oncology. It markets Nabi-HB for post-exposure prevention of hepatitis B infection and Aloprim for the treatment of chemotherapy-induced hyperuricemia. The company?s products under development include Nabi-HB Intravenous for prevention of re-infection with hepatitis B in HBV positive liver transplant patients; Civacir for the prevention of re-infection with hepatitis C in HCV positive liver transplant patients; ATG Fresenius-S, a Phase III clinical trial product for acute lung transplant rejection; IVIG and other Plasma fractions under pre-clinical development for various immune deficiencies and coagulation disease; and StaphVAX for protection against types 5 and 8 S. aureus infections. Its products under development also include Altastaph for treatment and/or protection of types 5 and 8 S. aureus infections; S. aureus 336 and S. epidermidis vaccine and corresponding antibodies for protection against S. epidermidis and type 336 infections; Panton-Valentine Leukocidin under preclinical development for the protection and/or treatment against the PVL toxin; Alpha Toxin for protection and/or treatment against the S.aureus alpha toxin; NicVAX, a Phase IIb clinical trial product for treatment of nicotine addiction; and Anti-D product, a polyclonal antibody under pre-clinical development for treatment of immune thrombocytopenic purpura. In addition, Nabi Biopharmaceuticals offers contract manufacturing services primarily to research and development-stage companies. Nabi Biopharmaceuticals serves wholesalers, distributors, hospitals, home healthcare companies, pharmaceutical and diagnostic product manufacturers. It has strategic alliances with Novartis, Talecris Biotheraputics, ProMetic, and Fresenius Biotech. The company was founded in 1967 and is headquartered in Boca Raton, Florida.

www.WallstreetStockReview.com

WallStreetStockReview.com is owned and operated by Iron Consulting.

Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering secu rities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.